arrow
P

Pablo Miguel

Institut Català d'Oncologia
H指数:10
被引数:322

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801

标题:西班牙免疫治疗和靶向治疗时代未知原发灶黑色素瘤的特征:前瞻性真实世界研究GEM 1801的结果

2025-12-200
PRE
Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study

西班牙晚期黏膜黑色素瘤患者的治疗效果:来自真实世界GEM1801研究的结果

2025-12-010
PRE
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801

应答率和长期生存率在晚期黑色素瘤患者中的表现:来自前瞻性队列研究gem-1801的数据

2025-11-280
OAAI
Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry

肢端黑色素瘤患者中基于抗PD-1抗体免疫疗法的效果不佳:西班牙黑色素瘤组(GEM)登记研究的结果

2025-08-210
PRE
Temporal dynamics of minesoil restoration in Southern Brazil: A two-decade monitoring of soil physical attributes and organic carbon content

南巴西矿区土壤恢复的时序动态:对土壤物理属性和有机碳含量二十年的监测

2025-06-120
OA
Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation

评估阿伐普利尼布(avapritinib)在具有胃肠道间质瘤和D842V-PDGFRA突变的真实世界西班牙病例中的有效性与安全性

2025-05-110
OA
Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAFV600-mutant melanoma in Spain: the BECARE (GEM-2002) trial
2025-02-260
OAAI
Sequence matters: Impact of first-line response in overall therapeutic outcome in differentiated thyroid cancer. Data from the Spanish national registry of thyroid cancer (REGETNE-Tiroides)

顺序很重要:一线反应对分化型甲状腺癌整体治疗效果的影响。来自西班牙甲状腺癌国家登记系统(REGETNE-Tiroides)的数据。

2024-09-010
PRE
Treatment outcomes of patients with anaplastic thyroid carcinoma (atc): Multicentric data from spanish national registry (regetne-tiroides)

间变性甲状腺癌(ATC)患者的治疗效果:来自西班牙国家登记系统(REGETNE-TIROIDES)的多中心数据

2024-09-010
PRE
Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
2023-10-010
PRE
Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002-BECARE)
2023-10-010
OAAI
Demography and clinical outcomes of adjuvant therapy in Spain: Results from GEM 1801 study
2022-09-010
PRE
Elderly patients (pts) with advanced melanoma: Results from the prospective real-world study GEM1801
2022-09-010
OAAI
Three-years real-world evidence of adjuvant dabrafenib plus trametinib (DT) in patients with resected melanoma in Spain (GEM 1901-DESCRIBE-AD)
2022-09-010
OAAI
Adjuvant dabrafenib plus trametinib (DT) treatment completion in patients with resected melanoma in Spain: A retrospective observational study (GEM 1901-DESCRIBE-AD)
2021-09-011
OAAI
Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study
2021-09-011
OAAI